US Antitrust Agencies Propose New Hart-Scott-Rodino Merger Control Rules to Require Enhanced Reporting of Pharma, Biological and Diagnostic Licenses
October 12, 2012
The Federal Trade Commission and Department of Justice recently announced revisions to the Hart-Scott-Rodino (HSR) Act's premerger notification rules to require enhanced reporting of transactions (including licenses) relating to patents involving pharmaceutical, biological and diagnostic products. This article discusses the background of HSR's application in this arena, the nature of the proposed changes, and areas requiring further clarification.
This article was published in the October 2012-I edition of the e‑Competitions Bulletin. A version of this article was published on October 4, 2012 as a Loeb & Loeb LLP Antitrust Alert. Click here to read the full alert.
Michael Jahnke is a partner in the Washington, DC and New York offices of Loeb & Loeb LLP. He specializes in counseling clients concerning antitrust issues in connection with litigation and proposed M&A transactions, joint ventures and other business conduct, advocates before the FTC and Department of Justice to resolve or limit antitrust issues throughout the government merger review process, and directs clients' compliance with governmental requests.